id: acamprosate_treatment_to_abstinence_maintenance
name: Acamprosate Treatment for AUD â†’ Alcohol Abstinence Maintenance
from_node:
  node_id: acamprosate_treatment
  node_name: Acamprosate Treatment for AUD
to_node:
  node_id: abstinence_maintenance
  node_name: Alcohol Abstinence Maintenance
direction: positive
category: healthcare_access
mechanism_pathway:
- 'Step 1: Acamprosate is prescribed as pharmacotherapy to assist in abstinence for
  AUD patients'
- 'Step 2: Acamprosate modulates glutamatergic neurotransmission altered by chronic
  alcohol exposure'
- 'Step 3: Medication reduces withdrawal symptoms and craving intensity'
- 'Step 4: Reduced neurobiological drive to drink supports sustained abstinence in
  appropriately selected patients'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: Laura B Ferguson et al. 2022. "RNA biomarkers for alcohol use
    disorder.." *Frontiers in molecular neuroscience*. https://doi.org/10.3389/fnmol.2022.1032362
last_updated: '2025-12-02'
version: '1.0'
llm_metadata:
  extracted_by: claude-sonnet-4-5-20250929
  extraction_date: '2025-12-02T18:12:06.675086'
  batch_id: msgbatch_01AKnPJgzm7Fk9qubgAz9GaD
moderators:
- name: non_reward_drinking_phenotype
  direction: strengthens
  strength: moderate
  description: Patients who drink primarily for relief of negative affect (rather
    than reward) may respond better to acamprosate than naltrexone
